The coronavirus disease 2019 (COVID‐19) pandemic has particularly affected countries with weakened health services in Latin America, where proper patient management could be a critical step to address the epidemic. In this study, we aimed to characterize and identify which epidemiological, clinical, and paraclinical risk factors defined COVID‐19 infection from the first confirmed cases through the first epidemic wave in Venezuela. A retrospective analysis of consecutive suspected cases of COVID‐19 admitted to a sentinel hospital was carried out, including 576 patient cases subsequently confirmed for severe acute respiratory syndrome coronavirus 2 infection. Of these, 162 (28.1%) patients met the definition criteria for severe/critical disease, and 414 (71.2%) were classified as mild/moderate disease. The mean age was 47 (SD 16) years, the majority of which were men (59.5%), and the most frequent comorbidity was arterial hypertension (23.3%). The most common symptoms included fever (88.7%), headache (65.6%), and dry cough (63.9%). Severe/critical disease affected mostly older males with low schooling (p < 0.001). Similarly, higher levels of glycemia, urea, aminotransferases, total bilirubin, lactate dehydrogenase, and erythrocyte sedimentation rate were observed in severe/critical disease patients compared to those with mild/moderate disease. Overall mortality was 7.6% (44/576), with 41.7% (28/68) dying in hospital. We identified risk factors related to COVID‐19 infection, which could help healthcare providers take appropriate measures and prevent severe clinical outcomes. Our results suggest that the mortality registered by this disease in Venezuela during the first epidemic wave was underestimated. An increase in fatalities is expected to occur in the coming months unless measures that are more effective are implemented to mitigate the epidemic while the vaccination process is ongoing.
Numerous reports of neuropsychiatric symptoms highlighted the pathologic potential of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its relationship the onset and/or exacerbation of mental disease. However, coronavirus disease 2019 (COVID‐19) treatments, themselves, must be considered as potential catalysts for new‐onset neuropsychiatric symptoms in COVID‐19 patients. To date, immediate and long‐term neuropsychiatric complications following SARS‐CoV‐2 infection are currently unknown. Here we report on five patients with SARS‐CoV‐2 infection with possible associated neuropsychiatric involvement, following them clinically until resolution of their symptoms. We will also discuss the contributory roles of chloroquine and dexamethasone in these neuropsychiatric presentations.
La enfermedad por Coronavirus 2019 (COVID-19) continúa siendo un serio problema de salud pública en todo el mundo, sin embargo, hasta la fecha, existe información limitada sobre el comportamiento de esta pandemia en América Latina y en particular en Venezuela. En este trabajo se describe la experiencia del Hospital Universitario de Caracas (HUC) durante la pandemia de la COVID-19. Posterior al reporte del primer caso de infección en el país el 13 de marzo del 2020, el HUC instauró una carpa para la atención y diagnóstico de pacientes sospechosos de la COVID-19; para el 31 de agosto un total de 6 532 pacientes habían sido atendidos en el HUC, y se habían realizado 1 589 pruebas de PCR-RT, confirmándose la infección en 732 (46 %) pacientes, con una edad media de 47 años (12-82), siendo la mayoría hombres (57,7 %). El subregistro de casos ha sido un factor común en el desarrollo de la pandemia COVID-19 en todos los países, Venezuela no es la excepción. Los estudios prospectivos nos advierten de una mayor frecuencia de eventos catastróficos en las próximas décadas, por lo que se hace necesario preparar a las sociedades para anticipar y gestionar los riesgos, esta pandemia puede ser la primera de muchas por venir.
2 June 2023 in Travel Medicine and Infectious Disease